Xenon Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026. The company posted a net loss of $110.7 million and research and development expenses of $99.2 million. Cash, cash equivalents, and marketable securities totaled $1.2 billion as of June 30, 2026, providing a cash runway into 2029. The company announced that its New Drug Application (NDA) submission for azetukalner in focal onset seizures is on track for the third quarter of 2026 following a pre-NDA meeting with the FDA. Phase 3 studies X-TOLE3 and X-ACKT continue to enroll, while top-line data from the Phase 3 X-NOVA2 study in major depressive disorder is expected in the first half of 2027. Xenon Pharmaceuticals Inc. operates in the biopharmaceutical industry, focusing on drug discovery and clinical development for neurological and psychiatric disorders.

"Xenon Pharmaceuticals Inc. announced the results of its June 2, 2026, annual meeting, where shareholders approved the 2026 Equity Incentive Plan and elected eight directors. Approximately 93.54% of the company's common shares were represented at the meeting, which also included the approval of executive compensation and the appointment of PricewaterhouseCoopers LLP as auditor."